TARA
Protara Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$276.52M
P/E Ratio
—
EPS
$-1.36
Beta
1.52
52W High
$7.82
52W Low
$2.77
50-Day MA
$5.17
200-Day MA
$5.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.69M |
| Operating Margin | 0.00% |
| Return on Equity | -37.30% |
| Return on Assets | -24.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.67 |
| Price-to-Book | 1.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $56.20M |
| Float | $49.48M |
| % Insiders | 2.39% |
| % Institutions | 82.36% |
Historical Volatility
HV 10-Day
86.18%
HV 20-Day
68.19%
HV 30-Day
60.47%
HV 60-Day
60.61%
HV Rank
26.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($26.57 target)
2
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026